- Home
- DWSN vs XOMAP Comparison
DWSN vs XOMAP Comparison
Compare DWSN & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DWSN
- XOMAP
- Stock Information
- Founded
- DWSN 1952
- XOMAP N/A
- Country
- DWSN United States
- XOMAP United States
- Employees
- DWSN N/A
- XOMAP 13
- Industry
- DWSN Oil & Gas Production
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- DWSN Energy
- XOMAP Health Care
- Exchange
- DWSN Nasdaq
- XOMAP Nasdaq
- Market Cap
- DWSN N/A
- XOMAP N/A
- IPO Year
- DWSN N/A
- XOMAP N/A
- Fundamental
- Price
- DWSN $1.39
- XOMAP $25.32
- Analyst Decision
- DWSN
- XOMAP
- Analyst Count
- DWSN 0
- XOMAP 0
- Target Price
- DWSN N/A
- XOMAP N/A
- AVG Volume (30 Days)
- DWSN 9.7K
- XOMAP N/A
- Earning Date
- DWSN 11-12-2024
- XOMAP N/A
- Dividend Yield
- DWSN N/A
- XOMAP N/A
- EPS Growth
- DWSN N/A
- XOMAP N/A
- EPS
- DWSN N/A
- XOMAP N/A
- Revenue
- DWSN $82,775,000.00
- XOMAP N/A
- Revenue This Year
- DWSN N/A
- XOMAP N/A
- Revenue Next Year
- DWSN N/A
- XOMAP N/A
- P/E Ratio
- DWSN N/A
- XOMAP N/A
- Revenue Growth
- DWSN N/A
- XOMAP N/A
- 52 Week Low
- DWSN $1.21
- XOMAP N/A
- 52 Week High
- DWSN $2.22
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- DWSN 47.75
- XOMAP 38.15
- Support Level
- DWSN $1.21
- XOMAP $25.82
- Resistance Level
- DWSN $1.45
- XOMAP $25.52
- Average True Range (ATR)
- DWSN 0.10
- XOMAP 0.10
- MACD
- DWSN 0.00
- XOMAP -0.03
- Stochastic Oscillator
- DWSN 60.00
- XOMAP 3.23
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.